Acceleron  

Publications

The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium; November 2015
+ DOWNLOAD PDF